Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently begins in childhood and can significantly impact quality of life. Baricitinib, an oral selective Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in pediatric patients with moderate-to-severe AD...
A. Wollenberg, A. Torrelo, Masanori Ikeda et al.· SKIN The Journal of Cutaneou...· 0 citations
Therapeutic patient education (TPE) is increasingly seen as an essential part of managing atopic dermatitis (AD), helping to connect clinical advice with real‐world adherence. This review aims to summarise current TPE approaches in AD, identify ongoing barriers to adherence, and examine innovations like digital healt...
J. Stalder, H. Aubert, S. Barbarot et al.· JEADV Clinical Practice· 0 citations
BACKGROUND
Elevated IgE levels are common in atopic dermatitis (AD). Although their role in AD pathogenesis is unclear, elevated IgE levels may be associated with disease exacerbation.
OBJECTIVE
To investigate the association of total IgE and/or disease severity with flares and dupilumab's impact on IgE levels and fl...
Brian S. Kim, Lisa A. Beck, E. Simpson et al.· Journal of Allergy and Clini...· 0 citations
Ruxolitinib cream applied as needed over 44 weeks was well tolerated and demonstrated disease control in children aged 2-11 years, consistent with findings in adolescents and adults.
A. Paller, L. Stein Gold, E. Simpson et al.· Journal of American Academy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.